CELL INTELLIGENCE · 肿瘤细胞治疗研究

通过整合全身药物组合与溶瘤腺病毒免疫治疗，探索 ccRCC 的新型治疗策略

Novel therapeutic strategies for ccRCC through integration of systemic drug combinations and oncolytic adenovirus immunotherapy.

这些发现表明，将靶向治疗与溶瘤病毒治疗相结合，有望克服 ccRCC 当前的治疗局限。此外，使用先进的三维人源相关 PDC 模型提供了一个可扩展的平台，用于评估联合治疗、支持个性化治疗策略，并促进适用于 ccRCC 及其他癌症类型的治疗方法的开发。

共表达 IL-12 与 shVEGF 的溶瘤腺病毒增强免疫检查点阻断治疗肾细胞癌：体外、器官芯片与体内评价

Oncolytic adenovirus co-expressing IL-12 and shVEGF potentiates immune checkpoint blockade for treatment of renal cell carcinoma: in vitro, organ-on-a

骨肿瘤学前沿进展——癌症与骨学会 2024 年会亮点

Cutting edge developments in bone oncology - Highlights from the Cancer and Bone Society 2024 annual meeting.

利用 TILT-517 溶瘤腺病毒和检查点阻断增强肾细胞癌的抗肿瘤免疫

Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma.

免疫肿瘤治疗药物的临床开发

Clinical development of immuno-oncology therapeutics.

免疫调节性细胞因子在新型 NK 细胞肿瘤治疗开发中的关键作用

The key role of immunomodulatory cytokines for the development of novel NK cell-based cancer therapies.

晚期透明细胞肾细胞癌的新兴免疫治疗方法

Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.

溶瘤腺病毒介导的 CCL5 与 IL12 表达促进靶向 CA9 的 CAR-T 疗法治疗肾细胞癌

Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma.

一种制胜的新组合？迈向肿瘤学临床应用

A Winning New Combination? Toward Clinical Application in Oncology.

免疫治疗作为脑与脊髓肿瘤的新治疗途径

Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.